Latest Conference Articles

Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of July.

Unlock exclusive insights from SDPA 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips. Share with us to access the full recap.

Catch up on coverage from the fourth and final day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

Expert our review of the top pearls, clinical strategies, and practice-changing tips from leading voices in dermatology at SDPA’s 2025 Summer Conference.

Test your knowledge of key words, terms, and pearls associated with this weekend's SDPA Annual Summer Dermatology Conference.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

A poster from SDPA 2025 showed brodalumab maintains a consistent safety profile with no completed suicides and low infection rates.

Eileen Cheever, MPAS, PA-C, highlights the growing role of JAK inhibitors in dermatology, including emerging data on prurigo nodularis and adolescent alopecia areata.

Catch up on coverage from the third day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

At SDPA 2025, a poster evaluating the STRATUM trial showed roflumilast foam 0.3% effectively treats seborrheic dermatitis with minimal pigment changes.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Ongoing maintenance therapy is essential to avoid relapse and preserve gains in repigmentation for patients with vitiligo, according to Gina Mangin, MPAS, PA-C.

Orit Markowitz, MD, shares how a color-focused strategy helps spot early malignancies—even 2-mm lesions—across all skin tones.

A yearlong study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Catch up on coverage from the second day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

Subcutaneous spesolimab maintained durable GPP control for 12 months after rapid clearance from IV spesolimab in a high-risk elderly patient.

Adam Friedman, MD, FAAD, outlines a stepwise approach to treating chronic hand eczema, from vehicle selection to systemic therapies and future innovations.

Orit Markowitz, MD, shares how her color wheel method boosts diagnostic clarity in dermoscopy by simplifying how clinicians assess benign lesions.

A poster at SDPA highlights that dermatologists play a vital role in early detection of metastatic breast cancer, with skin changes often serving as the initial clue of internal disease recurrence.

Adam Friedman, MD, FAAD, breaks down how to differentiate chronic hand eczema from similar conditions using history, morphology, and key clinical clues.

Apremilast improved joint symptoms and quality of life in patients with early oligoarticular PsA, with consistent efficacy across all BMI categories.

Janelle Ball of BC Educators offers actionable tips to boost prior authorization success and improve patient support in dermatology practices.

Catch up on coverage from the first day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

A poster at SDPA 2025 highlights the importance of early biopsy and genetic testing in aggressive cSCC, even in young patients without classic risk factors.

Almirall showcased groundbreaking research on atopic dermatitis, psoriasis, and actinic keratosis at the 2025 ICD.